Natera

Judge Reduces Major False Advertising Verdict Against Natera, Company Plans Appeal

by

SAN FRANCISCO — A federal judge has reduced a substantial jury award against Natera, a cancer screening company, but declined to grant the firm’s request for a new trial. U.S. District Judge Edward Chen decreased the jury’s original award of $292.5 million for false advertising by $5.5 million on Monday. Following the court’s decision, Natera announced plans to appeal. The case stems from a ruling made by a jury in San Francisco last year, which found in favor of Guardant Health, determining that Natera should compensate its competitor with $75 million in future damages and … Read more

Guardant Health Wins $292.5 Million in Landmark False Advertising Case Against Rival Natera

by

San Francisco, California – In a decisive courtroom victory, Guardant Health, a prominent manufacturer of medical diagnostics, was awarded $292.5 million in damages on Monday. This followed a federal jury’s verdict that competitor Natera had engaged in false advertising concerning its colorectal cancer screening tests. The case, which captured industry and public attention, centered on accusations that Natera’s claims about its tests were misleading, thereby negatively impacting Guardant Health’s market standing and reputation. The substantial award consisted of both actual and punitive damages, highlighting the severity of the claims. This legal battle signifies a pivotal … Read more

KAS Legal Team Secures $292.5 Million Victory Against Natera in High-Stakes Biotech Patent Dispute

by

Wilmington, Delaware – In a landmark legal battle that pitted two major players in the medical diagnostics sector against each other, KAS, a legal team representing Guardant Health, secured a stunning $292.5 million jury verdict against Natera Inc. The verdict, delivered after rigorous deliberations, marks a significant turn in the ongoing tensions revolving around patent infringements within the industry. Guardant Health, renowned for its ground-breaking contributions to cancer diagnostics, accused Natera Inc. of infringing on its patented technology, which plays a crucial role in non-invasive cancer tests. These tests are instrumental in detecting early signs … Read more

Jury Awards Guardant Health $292.5 Million in False Advertising Case Against Rival Natera

by

San Francisco, CA – A federal jury in California delivered a significant verdict favoring Guardant Health in a legal battle against Natera Inc., awarding the medical test manufacturer a substantial $292.5 million in damages. The jury found that Natera had engaged in false advertising regarding its colorectal cancer test, which it claimed was superior to Guardant Health’s Reveal test. The decision arrived after a contentious legal confrontation, underscoring the fierce competition within the biotechnology sector, particularly in the development and marketing of cancer diagnostic tests. This lawsuit highlights the critical role of accurate and truthful … Read more